Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers

5 Apr 2024

Abstract excerpt

Cyclin-dependent kinases (CDK2, CDK4, CDK6), cyclin D1, cyclin E1 and phosphorylated retinoblastoma (pRB1) are key regulators of the G1/S cell cycle checkpoint and may influence platinum response in ovarian cancers. CDK2/4/6 inhibitors are emerging targets in ovarian cancer therapeutics. In the current study, we evaluated the prognostic and predictive significance of the CDK2/4/6-cyclin D1/E1-pRB1 axis in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38612869
DOI: 10.3390/ijms25074060

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian CancersPMID 38612869Read ↗

Differential Expression and Prognostic Significance of CDK1 and CDK6 in Breast Cancer: A Multi-Omics ApproachSemantic proximity Read ↗

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian CancerSemantic proximity Read ↗

Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer TreatmentSemantic proximity Read ↗

Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncologySemantic proximity Read ↗

Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer TreatmentSemantic proximity Read ↗

Stabilization of GTSE1 by cyclin D1–CDK4/6-mediated phosphorylation promotes cell proliferation with implications for cancer prognosisSemantic proximity Read ↗

Stabilization of GTSE1 by cyclin D1-CDK4/6-mediated phosphorylation promotes cell proliferation: relevance in cancer prognosisSemantic proximity Read ↗

Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.Semantic proximity Read ↗

CDK4 and CDK6 kinases: From basic science to cancer therapySemantic proximity Read ↗

CDK1 as a Novel Potential Biomarker for Predicting the Prognosis of endometrioid ovarian carcinomaSemantic proximity Read ↗

Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targetsSemantic proximity Read ↗

Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.